

#2510  
3/20/03

PATENT  
ATTORNEY DOCKET NO. 50013/002003



Certificate of Mailing: Date of Deposit: March 3, 2003

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Kristina Levites

Printed name of person mailing correspondence

  
Signature of person mailing correspondence

TECH CENTER 1600/2900

MAR 19 2003

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Philip E. Branton et al. Art Unit: 1632  
Serial No.: 09/214,478 Examiner: Shin-Lin Chen  
Filed: June 7, 1999 Customer No.: 21559  
Title: ADENOVIRUS E4 PROTEINS FOR INDUCING CELL DEATH

Commissioner for Patents  
Washington, D.C. 20231

REPLY TO OFFICE ACTION

In reply to the Office Action mailed in the above-captioned case on September 3, 2002, applicants submit the following amendments and remarks.

AMENDMENTS

Kindly cancel claims 61-63 and amend claims 88 and 95 to read as follows:

88. (Three times amended) A pharmaceutical composition comprising (i) an expression vector comprising a nucleic acid encoding an E4orf4 polypeptide comprising the sequence of SEQ ID NO.: 4 and capable of inducing apoptosis, and (ii) a pharmaceutically acceptable carrier, wherein said nucleic acid is operably linked to a heterologous regulatory sequence for expression of said E4orf4 polypeptide in a mammalian cell, and wherein E4 polypeptides other than said E4orf4 polypeptide are not expressed by said vector.

10